DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vexol (Rimexolone Ophthalmic) - Summary

 
 



VEXOL SUMMARY

Vexol® 1%
(rimexolone ophthalmic suspension)

VEXOL® 1% Ophthalmic Suspension is a sterile, multi-dose topical ophthalmic suspension containing the corticosteroid, rimexolone.

VEXOL® 1% (rimexolone ophthalmic suspension) is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.


See all Vexol indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Vexol (Rimexolone Ophthalmic)

[Efficacy of prednisolone and rimexolone in HLA-B27 positive patients with acute anterior uveitis] [2005.09]
PURPOSE: To compare the efficacy and safety of prednisolone acetate 1% vs. rimexolone 1% ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27+ patients... CONCLUSION: Rimexolone 1% is as effective as prednisolone acetate 1% in the treatment of mild to moderate AAU HLA-B27+. IOP increased in both groups, but this variation was not clinically significant.

Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study. [2005.08]
PURPOSE: To compare the efficacy, safety and patient comfort of two topical steroids (prednisolone 1% and rimexolone 1%) and a topical non-steroidal anti-inflammatory agent (ketorolac tromethamine 0.5%) after extracapsular cataract extraction... CONCLUSIONS: Ketorolac tromethamine provides good control of intraocular inflammation after cataract extraction without the risk of a steroidal IOP increase, which was also not observed under rimexolone therapy. The best surface inflammation control and patient comfort was observed with prednisolone, which remains a good choice.

[0.1% dexamathasone and 1% rimexolone. A comparative study in the postoperative treatment after cataract extraction] [2009.06]
PURPOSE: To compare the efficiency and secondary effects of using 1% rimexolone or 0.1% dexamethasone as postoperative treatment for cataract surgery... CONCLUSIONS: Rimexolone is as efficient and safe as dexamethasone for the treatment of patients undergoing cataract extraction.

Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. [2008.08]
Purpose: To compare the efficacy and safety of rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods: Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes) was compared with that of rimexolone 1% one eye drop every 4 h (n = 44 eyes) in an eighteen day course...

Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. [2007.08.31]
Purpose: To compare the efficacy and safety of rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods: Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes) was compared with that of rimexolone 1% one eye drop every 4 h (n = 44 eyes) in an eighteen day course...

more studies >>

Clinical Trials Related to Vexol (Rimexolone Ophthalmic)

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye [Completed]

more trials >>


Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012